myChoice CDx test

September 24, 2020September 24, 2020

Lynparza Combo Recommended by EU Committee as First-line Maintenance for Advanced Ovarian Cancer

News

Lynparza (olaparib), in combination with bevacizumab, has been recommended for approval in the European Union (EU) as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who ... Read more

May 12, 2020January 12, 2021

FDA Approves Lynparza Combo as First-line Maintenance Therapy for Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who responded to platinum-based chemotherapy. This ... Read more

February 19, 2020February 19, 2020

Myriad Asks FDA to Approve myChoice CDx to Find Potential Lynparza Candidates

News

Myriad Genetics submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of its myChoice CDx test to identify ovarian cancer patients likely to benefit from first-line ... Read more

January 23, 2020February 6, 2020

FDA Asked to Approve Test of Ovarian Cancers Likely to Respond to Zejula Maintenance Therapy

News

Myriad Genetics has filed a supplementary premarket approval (sPMA) application with the U.S. Food and Drug Administration (FDA) seeking approval of its myChoice CDx test to identify advanced ovarian cancer patients more likely ... Read more